Envestnet Asset Management Inc. Has $24.46 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

Envestnet Asset Management Inc. cut its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 18.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 339,284 shares of the medical equipment provider's stock after selling 75,401 shares during the quarter. Envestnet Asset Management Inc. owned 0.15% of Hologic worth $24,459,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in HOLX. HighTower Advisors LLC boosted its holdings in shares of Hologic by 9.8% in the 3rd quarter. HighTower Advisors LLC now owns 22,603 shares of the medical equipment provider's stock valued at $1,832,000 after buying an additional 2,012 shares during the period. Stifel Financial Corp raised its position in shares of Hologic by 115.8% during the 3rd quarter. Stifel Financial Corp now owns 20,354 shares of the medical equipment provider's stock worth $1,658,000 after purchasing an additional 10,924 shares during the period. MML Investors Services LLC boosted its position in Hologic by 10.1% during the 3rd quarter. MML Investors Services LLC now owns 41,038 shares of the medical equipment provider's stock valued at $3,343,000 after purchasing an additional 3,775 shares during the period. Barclays PLC grew its stake in Hologic by 47.6% during the 3rd quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider's stock worth $58,507,000 after buying an additional 231,578 shares during the last quarter. Finally, M&T Bank Corp lifted its stake in Hologic by 0.8% in the third quarter. M&T Bank Corp now owns 26,368 shares of the medical equipment provider's stock valued at $2,148,000 after buying an additional 201 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Remove Ads

Hologic Stock Up 2.0 %

Hologic stock traded up $1.15 during mid-day trading on Thursday, hitting $57.65. 2,068,699 shares of the company's stock were exchanged, compared to its average volume of 1,930,347. The stock has a market cap of $12.94 billion, a P/E ratio of 18.17, a P/E/G ratio of 2.14 and a beta of 0.82. The stock has a 50 day moving average of $61.87 and a two-hundred day moving average of $71.15. Hologic, Inc. has a 1-year low of $56.00 and a 1-year high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on HOLX. Needham & Company LLC lowered shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 target price for the company. in a research note on Monday, February 3rd. Raymond James reaffirmed an "outperform" rating and set a $90.00 target price (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Evercore ISI cut their price objective on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a research note on Thursday, February 6th. Citigroup lowered their target price on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Finally, Leerink Partners cut Hologic from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.